Fondaparinux has the edge over enoxaparin in ACS

Results of the OASIS 5 study showed that although fondaparinux sodium [Arixtra] has similar efficacy to enoxaparin sodium in the treatment of acute coronary syndromes (ACS), fondaparinux is associated with a significantly lower risk of bleeding events. The study, presented at the European Society of Cardiology (ESC) Annual Congress [Stockholm, Sweden; September 2005], showed that there was no difference between the two treatments in preventing myocardial infarction (MI), death and ischaemia within 9 days after an acute coronary event. However, patients receiving fondaparinux had fewer bleeding episodes and a lower 6-month mortality rate than patients receiving enoxaparin.